Why Doctor Care Anywhere (ASX:DOC) is soaring 12% today

The telehealth company has announced a new series of remote appointment options.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Doctor Care Anywhere Group PLC (ASX: DOC) share price has leapt today after the company announced a new offering to patients.

The telehealth company has introduced a new operating model, moving from the single option of a 20-minute virtual consultation with a doctor to multiple options for treatment advice. 

At time of writing, the Doctor Care Anywhere share price is up 12%, trading at 46.5 cents apiece. 

An older woman clasps her hands with joy, smiling at the news on her computer as she sits at her kitchen bench..

Image source: Getty Images

New Telehealth options in place for patients

With COVID-19 spearheading the uptake of remote appointments, the Federal Health Department this week announced a $308.6 million injection into the primary care health system. This includes a $106 million portion for permanent Telehealth for Australians.

The announcement times well for Doctor Care Anywhere, with its new model including options such as shorter appointments, meeting with a nurse, or completing a QuickConsult survey to be reviewed and returned with written advice or a prescription. 

The company said this model would assist in "the challenge of clinical workforce shortages and ever-increasing healthcare demand". 

In addition, the telehealth company announced that its current agreement held with AXA Health would now vary to allow nurses to "make decisions in the assessment, diagnosis, and treatment of patients and to prescribe medication".

Doctor Care Anywhere share price snapshot

The Doctor Care Anywhere share price has fallen 61.67% since the company listed on the ASX in December last year. The company saw a high volume of trading on Monday following the government's healthcare investment.

Based on the current share price, the telehealth company has a market capitalisation of around $89 million.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Doctor Care Anywhere Group PLC. The Motley Fool Australia has recommended Doctor Care Anywhere Group PLC. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »